Bonesupport Holding (2B4) Stock Overview
An orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2B4 from our risk checks.
2B4 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 17.46 |
| 52 Week High | SEK 35.36 |
| 52 Week Low | SEK 16.18 |
| Beta | 0.43 |
| 1 Month Change | 3.31% |
| 3 Month Change | -26.20% |
| 1 Year Change | -45.06% |
| 3 Year Change | 141.66% |
| 5 Year Change | 142.50% |
| Change since IPO | 491.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2B4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.9% | 4.3% | 2.4% |
| 1Y | -45.1% | -36.4% | 15.5% |
Return vs Industry: 2B4 underperformed the German Biotechs industry which returned -35.3% over the past year.
Return vs Market: 2B4 underperformed the German Market which returned 15.3% over the past year.
Price Volatility
| 2B4 volatility | |
|---|---|
| 2B4 Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2B4 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2B4's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 143 | Torbjorn Skold | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| 2B4 fundamental statistics | |
|---|---|
| Market cap | €1.15b |
| Earnings (TTM) | €14.13m |
| Revenue (TTM) | €104.11m |
Is 2B4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2B4 income statement (TTM) | |
|---|---|
| Revenue | SEK 1.12b |
| Cost of Revenue | SEK 82.74m |
| Gross Profit | SEK 1.04b |
| Other Expenses | SEK 884.47m |
| Earnings | SEK 151.92m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 24, 2026
| Earnings per share (EPS) | 2.31 |
| Gross Margin | 92.61% |
| Net Profit Margin | 13.57% |
| Debt/Equity Ratio | 0% |
How did 2B4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/08 08:26 |
| End of Day Share Price | 2026/01/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bonesupport Holding AB (publ) is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Erik Cassel | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |